drugset / Trial / NCT06217146

A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.

NCT06217146

Terminated 24 enrolled M. H MediCane Ltd.
Non-randomizedParallel-groupTriple-blindTreatment

Summary

This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's medical cannabis oil extracted from MediCane's proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of care (SoC), in reducing agitation and disruptive behaviors in subjects with dementia including probable AD.

Timeline

Start
2022-10-12
Primary completion
2024-03-10
Completion
2024-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified